Immunofluorescence in brain cancer tissues to reveal potential for immune checkpoint inhibitors treatment
2018
Brigham and Women’s Hospital, Boston, USA
Surgical resection of craniopharyngiomas is challenging, and recurrence is common, frequently leading to profound morbidity. In the present study, the researchers explored the feasibility of targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint pathway in craniopharyngiomas. The researchers mapped and quantified PD-L1 and PD-1 expression in patients' resections using immunohistochemistry, immunofluorescence, and RNA in situ hybridization. Also, they used tissue-based cyclic immunofluorescence to map the spatial distribution of immune cells and characterize cell cycle and signalling pathways in tumor cells that intrinsically express PD-1. All results indicate that targeting PD-L1 and/or PD-1 in craniopharyngioma might be an effective therapeutic strategy.
Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma
Sandro Santagata
Added on: 07-29-2021
[1] https://academic.oup.com/neuro-oncology/article/20/8/1101/4917565[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
